CN117242092A - Vegfa结合分子 - Google Patents

Vegfa结合分子 Download PDF

Info

Publication number
CN117242092A
CN117242092A CN202280015698.7A CN202280015698A CN117242092A CN 117242092 A CN117242092 A CN 117242092A CN 202280015698 A CN202280015698 A CN 202280015698A CN 117242092 A CN117242092 A CN 117242092A
Authority
CN
China
Prior art keywords
antigen binding
vegfa
binding molecule
fold
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280015698.7A
Other languages
English (en)
Chinese (zh)
Inventor
雅思杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duote Biological Private Ltd
Original Assignee
Duote Biological Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duote Biological Private Ltd filed Critical Duote Biological Private Ltd
Publication of CN117242092A publication Critical patent/CN117242092A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/515—Angiogenesic factors; Angiogenin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202280015698.7A 2021-02-19 2022-02-18 Vegfa结合分子 Pending CN117242092A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10202101681W 2021-02-19
SG10202101681W 2021-02-19
PCT/EP2022/054123 WO2022175474A1 (en) 2021-02-19 2022-02-18 Vegfa-binding molecules

Publications (1)

Publication Number Publication Date
CN117242092A true CN117242092A (zh) 2023-12-15

Family

ID=80685523

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202280015698.7A Pending CN117242092A (zh) 2021-02-19 2022-02-18 Vegfa结合分子
CN202280029374.9A Pending CN117279941A (zh) 2021-02-19 2022-02-18 Vegfa结合分子

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202280029374.9A Pending CN117279941A (zh) 2021-02-19 2022-02-18 Vegfa结合分子

Country Status (9)

Country Link
US (2) US20240228602A9 (https=)
EP (2) EP4294839A1 (https=)
JP (2) JP2024513644A (https=)
KR (2) KR20230165902A (https=)
CN (2) CN117242092A (https=)
AR (1) AR124917A1 (https=)
AU (2) AU2022223337A1 (https=)
CA (2) CA3208389A1 (https=)
WO (2) WO2022175481A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024240171A1 (zh) 2023-05-22 2024-11-28 上海君实生物医药科技股份有限公司 抗pd-1-抗vegf的双特异性抗体、其药物组合物及其用途

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119790077A (zh) * 2022-09-14 2025-04-08 寻济生物科技（北京）有限公司 一种抗vegfa融合蛋白及其制备方法和应用
AU2023340044A1 (en) * 2022-09-14 2025-04-03 Quaerite Biopharm Research (Beijing) Co., Ltd. Anti-vegfa antibody or antigen-binding fragment thereof and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100291103A1 (en) * 2007-06-06 2010-11-18 Domantis Limited Polypeptides, antibody variable domains and antagonists
US20120225081A1 (en) * 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
US20140205604A1 (en) * 2011-07-27 2014-07-24 Glaxo Group Limited Antigen binding constructs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100883430B1 (ko) * 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
WO2016072938A1 (en) 2014-11-05 2016-05-12 Nanyang Technological University Stabilized and autonomous antibody vh domain
EP3078674B1 (en) * 2015-01-06 2020-09-23 Zhuhai Essex Bio-pharmaceutical Co., Ltd. Anti-vegf antibody
WO2018126317A1 (en) * 2017-01-05 2018-07-12 Helix Biopharma Corporation Vegfr-2 car immune cells to treat cancers
CN110452297B (zh) * 2019-09-03 2020-04-14 上海洛启生物医药技术有限公司 抗vegf单域抗体及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100291103A1 (en) * 2007-06-06 2010-11-18 Domantis Limited Polypeptides, antibody variable domains and antagonists
US20120225081A1 (en) * 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
US20140205604A1 (en) * 2011-07-27 2014-07-24 Glaxo Group Limited Antigen binding constructs

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024240171A1 (zh) 2023-05-22 2024-11-28 上海君实生物医药科技股份有限公司 抗pd-1-抗vegf的双特异性抗体、其药物组合物及其用途

Also Published As

Publication number Publication date
JP2024513644A (ja) 2024-03-27
WO2022175474A1 (en) 2022-08-25
KR20230165902A (ko) 2023-12-05
AR124917A1 (es) 2023-05-17
AU2022223337A1 (en) 2023-09-21
CN117279941A (zh) 2023-12-22
US20240228602A9 (en) 2024-07-11
AU2022222311A1 (en) 2023-09-21
EP4294838A1 (en) 2023-12-27
JP2024512260A (ja) 2024-03-19
KR20230165901A (ko) 2023-12-05
JP7827737B2 (ja) 2026-03-10
US20240228601A9 (en) 2024-07-11
US20240132580A1 (en) 2024-04-25
WO2022175481A1 (en) 2022-08-25
US20240132579A1 (en) 2024-04-25
EP4294839A1 (en) 2023-12-27
CA3208389A1 (en) 2022-08-25
CA3208368A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
TWI883044B (zh) 使用her3抗原結合分子的癌症之治療及預防
US11780933B2 (en) HER3 antigen-binding molecules
CN115003333B (zh) Pvrig结合蛋白及其医药用途
JP7627687B2 (ja) Ｌｉｌｒｂ２に対するシングルドメイン抗体
JP7827737B2 (ja) Ｖｅｇｆａ結合分子
CN114437227A (zh) 双特异抗体及其应用
WO2023219147A1 (ja) Ｃｃｒ８検出用新規抗ｃｃｒ８抗体
CN112243443A (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
TWI782000B (zh) 抗ｇｐｒ２０抗體、其製造方法及其應用
HK40073393A (en) Bispecific antibody and use thereof
WO2025201493A1 (zh) Dll3结合分子及其用途
TW202241957A (zh) 抗ｐｄ－１抗體及其用途
EA046196B1 (ru) Однодоменные антитела, направленные против lilrb2
HK40036076A (en) Anti-trop-2 antibody, antigen binding fragment thereof and medical use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination